Research programme: antiviral vaccines - Vaxart
Alternative Names: Chikungunya vaccine - Vaxart; Hepatitis B vaccine - Vaxart; Herpes simplex virus vaccine - Vaxart; Zika virus vaccine - VaxartLatest Information Update: 26 Feb 2021
At a glance
- Originator Vaxart
- Class Hepatitis B vaccines; Papillomavirus vaccines; Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chikungunya virus infections; Hepatitis B; Herpes simplex virus infections; Herpes simplex virus type 2 infections; Zika virus infection
Most Recent Events
- 24 Feb 2021 Vaxart files for patent protection for proprietary technology, VAAST™ platform, and creations for oral vaccination using adenovirus and TLR3 agonists in USA and other countries
- 28 Dec 2020 No recent reports of development identified for preclinical development in Herpes simplex virus type-2 infections in USA (PO, Tablet)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Zika-virus-infection(Prevention) in USA (PO, Tablet)